Diabetes triples the risk for active tuberculosis, thus the increasing burden of type 2 diabetes will help to sustain the present tuberculosis epidemic. Recommendations have been made for bidirectional screening, but evidence is scarce about the performance of specifi c tuberculosis tests in individuals with diabetes, specifi c diabetes tests in patients with tuberculosis, and screening and preventive therapy for latent tuberculosis infections in individuals with diabetes. Clinical management of patients with both diseases can be diffi cult. Tuberculosis patients with diabetes have a lower concentration of tuberculosis drugs and a higher risk of drug toxicity than tuberculosis patients without diabetes. Good glycaemic control, which reduces long-term diabetes complications and could also improve tuberculosis treatment outcomes, is hampered by chronic infl ammation, drug-drug interactions, suboptimum adherence to drug treatments, and other factors. Besides drug treatments for tuberculosis and diabetes, other interventions, such as education, intensive monitoring, and lifestyle interventions, might be needed, especially for patients with newly diagnosed diabetes or those who need insulin. From a health systems point of view, delivery of optimum care and integration of services for tuberculosis and diabetes is a huge challenge in many countries. Experience from the combined tuberculosis and HIV/AIDS epidemic could serve as an example, but more studies are needed that include economic assessments of recommended screening and systems to manage concurrent tuberculosis and diabetes.
Introduction
Tuberculosis is a major global health problem. In 2012, 8·6 million people developed tuberculosis and 1·3 million died from the disease. 1 Diabetes increases the risk of developing active tuberculosis 2, 3 and is associated with worse tuberculosis treatment outcomes. 4 Globally, 15% of tuberculosis cases are estimated to be attributable to diabetes. 5 The International Diabetes Federation predicts that the number of people worldwide with diabetes will increase by 55% during the next 20 years, with the largest increase expected in Africa (+109%). 6 Therefore, diabetes will make an increasingly important contribution to the tuberculosis epidemic. Whether screening for diabetes in patients with tuberculosis (and the converse) is feasible and cost eff ective, and how those identifi ed with concurrent tuberculosis and diabetes can be best managed, are key research questions (panel 1).
In this Series paper, we focus on tuberculosis-endemic settings. We assess the epidemiology of tuberculosis and diabetes, screening for tuberculosis in patients with diabetes and the converse, and issues related to clinical management of concurrent tuberculosis and diabetes. We also discuss implications of the joint epidemic for health services and public health, and outline key questions for future research.
Panel 1: Example case history
A 45-year-old man presents with a 2 month history of a cough and night sweats to a lung clinic in Jakarta, Indonesia. He has no relevant medical history, has been a smoker for 25 years, and is not taking drugs. The patient's physical examination is unremarkable, but his chest radiograph shows abnormalities suggestive of tuberculosis and his sputum is positive for acid-fast bacilli. His HIV test is negative. Standard treatment for pulmonary tuberculosis is started. When he returns after 2 weeks he reports longstanding thirst and polyuria. An endocrinologist is consulted and type 2 diabetes is diagnosed, even though the patient has a healthy weight (BMI of 20·1 kg/m²). The patient is given oral diabetes drugs but his blood glucose concentrations remain high. He is referred for insulin treatment but does not attend the diabetes clinic. His sputum smear remains positive after 2 months of therapy, calling into question compliance to treatment. After a full 6 month course of tuberculosis treatment, he remains sputum smear positive and still has hyperglycaemia.
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Evidence shows that both type 1 and type 2 diabetes can increase tuberculosis risk. However, as type 2 diabetes accounts for 85-95% of global cases of diabetes the burden of comorbid disease from type 2 diabetes is much greater and thus the main focus of this paper. Diabetes prevalence is increasing substantially; from an estimated 151 million adults in 2000, 8 to 382 million in 2013, which is predicted to increase to 592 million in 2035. 6 Prevalence, number of undiagnosed cases, expenditure per case, and mortality, across the world varies greatly (fi gure 1). 6 Ongoing globalisation, urbanisation, population growth, and rural to urban migration (which might contribute to diabetes burden because of changes in environment and resulting putative risk factors such as obesity) in low-income and middle-income countries all contribute to increases in the burden of type 2 diabetes. 9, 10 The thrifty phenotype hypothesis, whereby sparse nutrition and fetal growth leads to metabolic adaptation, might account for how such changes rapidly increase diabetes prevalence in regions with undernutrition; 11, 12 fetal growth patterns and programming might be unable to biologically cope in new obesogenic environments. 11 Type 2 diabetes has historically been perceived as a disease of affl uence that is strongly associated with obesity and physical inactivity, but in low-income countries diabetes is also prevalent in populations who live in poor urban settings, with up to 15% of adults aff ected. 13 Diabetes prevalence is around 15-30% in patients with tuberculosis in some settings. As this fi gure is likely to increase, management of diabetes in patients with tuberculosis is becoming an inevitable part of clinical practice.
Two systematic reviews 2, 3 that together included 15 studies showed the risk of developing tuberculosis is at least tripled in individuals with diabetes, consistent across geographical regions, and that the increase in risk is highest in young people. However, few studies adjusted for confounders other than age and sex, there was variation in the quality of testing for both diseases, and the data from low-income and middle-income countries were scarce (fi gure 1).
2,3 A meta-analysis 2 of data from three prospective studies quantifi ed tuberculosis risk in people with diabetes compared to those without diabetes (relative risk 3·11, 95% CI 2·27-4·26). However, two of the included studies were done in individuals with renal failure, which is a risk factor for tuberculosis, and all were done in Asia. Other studies [14] [15] [16] have provided more recent data from low-income and middle-income countries and have used better case-ascertainment methods. HIV negative, but not HIV positive, individuals with diabetes in Tanzania had an increased risk of tuberculosis, which suggests that the eff ect of HIV overrides the risk conferred by diabetes.
14 Another study 17 showed the risk of tuberculosis was increased at levels of hyperglycaemia of less than present diabetes diagnostic cutoff s. A large, multicountry, longitudinal analysis 18 from low-income countries reported an increased tuberculosis risk in people with diabetes. Additionally, tuberculosis prevalence (odds ratio 4·7, 95% CI 1·0-22·5) and incidence (8·6, 1·9-40·4) were more likely to increase in countries where diabetes prevalence had increased during the past 10 years (between 1990-95 and 2003-04), and where per-capita base year gross domestic product was low (highest gross domestic product quintile against lowest quintile for tuberulcosis prevalence [0·09, 0·02-0·42] and tuberulcosis incidence [0·03, 0·01-0·14]). Few studies explicitly assess whether tuberculosis increases the risk of diabetes. 19 Induced hyperglycaemia or impaired glucose tolerance has been noted during the early phase of tuberculosis, but whether these symptoms are newly established, previously undiagnosed, or intermittent is unknown.
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Diabetes and the risk of poor tuberculosis outcomes
Diabetes is not only a risk factor for active tuberculosis, but also for poor tuberculosis treatment outcomes. A meta-analysis 4 showed that the combined outcome of tuberculosis treatment failure and death was signifi cantly higher in patients with diabetes than in those without diabetes (relative risk 1·69, 95% CI 1·36-2·12). Similarly, the risk of death during tuberculosis treatment (1·89, 1·52-2·36) and relapse following treatment (3·89, 2·43-6·23) were higher in patients with diabetes compared to those without diabetes. Six of nine studies that assessed sputum conversion reported that patients with tuberculosis and diabetes were more likely to remain sputum smear positive at 2-3 months after starting treatment for tuberculosis. 4 Severity of hyperglycaemia (as measured by HbA 1c ) did not seem to increase the risk of a poor tuberculosis outcome. 25 The eff ects of diabetes on outcomes of tuberculosis treatment are unlikely to be from diff erences in drug resistance; a systematic review 4 of 33 studies showed no association between drug-resistant tuberculosis and diabetes. However, many of these studies did not adjust for other key confounders 4 and only reported all-cause mortality. Therefore, a high proportion of deaths in patients with diabetes presenting with tuberculosis could be because of poor underlying health or advanced age. 4 An increasing number of studies have reported data from low-income and middle-income countries. 4, [26] [27] [28] [29] A prospective study 28 from Tanzania noted an increased risk of early death among HIV-negative individuals with tuberculosis and diabetes, compared to those without diabetes (relative risk of dying in fi rst 100 days 5·09, 95% CI 2·36-11·02), but no increased long-term risk, suggesting comorbidity is the key determinant. Another prospective study 30 from South Korea showed the combined eff ect of diabetes and smoking increased the risk of tuberculosis mortality by almost six times in the fi rst year (hazard ratio 5·78, 95% CI 1·09-30·56) after enrollmnet and tuberculosis treatment.
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Number of laboratories with smear microscopy capacity per 100 000 population, 2012 31 estimate that the present upward trend in diabetes prevalence (projected by the International Diabetes Federation to be a 55% rise in the number of people with diabetes by 2035) would off set the worldwide decreases in tuberculosis incidence by 3% by 2035, and by 8% in a pessimistic scenario (an 80% rise in the number of people with diabetes), 31 which might be realistic in regions where diabetes risk factors are increasing fastest. 32 The analysis did not account for onward tuberculosis transmission, and thereby underestimates the potential eff ect of diabetes. Clearly, further dynamic models with an economic investigative component are needed.
Patient management and screening
Screening for active tuberculosis in individuals with diabetes
Up to 2011, 12 studies had been undertaken for tuberculosis screening in individuals with diabetes. 33 Half these studies used radiography whereas the other half used radiography plus microbiological testing to identify tuberculosis in patients. 33 Only half the studies compared the results from people with diabetes with those in individuals without diabetes. 33 Unsurprisingly, a large variance was noted in the estimates of tuberculosis prevalence (from 1·7% in Sweden to 36% in South Korea); and in the numbers needed to be screened to detect one previously undetected case of tuberculosis (4-442, respectively). Table 1 contains the diff erent methods for tuberculosis screening, diagnosis, and potential pitfalls with their use in patients with diabetes. The yield (number needed to screen) and costeff ectiveness of diff erent tuberculosis tests mainly depends on the tuberculosis prevalence in any given setting and the sensitivity and cost of tests used. 33 The overall evidence base identifi ed by a systematic review 33 was weak and exposed an urgent need for further research. Several subsequent studies from various diff erent settings have been published since 2011, 17, 36, [39] [40] [41] [42] [43] [44] [45] [46] [47] and have shown that symptom screening and chest radiography for tuberculosis are operationally feasible in diabetes clinics in India and China (countries with a high tuberculosis burden (provisionally defi ned as 100 cases per 100 000 people; appendix). 40, 45, 46 Further studies are needed to provide reliable estimates of tuberculosis prevalence in individuals with diabetes, and whether any relation exists between duration of diabetes and glycaemic control. We did not fi nd any studies that used alternative tests in individuals with diabetes, such as computer-aided radiography reading 48 or Xpert MTB/RIF assay, a rapid automated molecular test that is being rolled out in settings with a high burden of tuberculosis. 37 Overall, tuberculosis in individuals with diabetes is relatively uncommon and so selective tuberculosis screening might be indicated. Clearly a low index of suspicion is needed for when a patient with diabetes presents with suggestive symptoms of tuberculosis such as a cough, weight loss, or a history of exposure to a patient with tuberculosis.
Screening for latent tuberculosis infection in individuals with diabetes
Latent tuberculosis infection can be detected with the tuberculin skin test or interferon gamma release assay, both of which screen for immunological memory. 49 Although the interferon gamma release assays can be slightly more specifi c and sensitive than a tuberculin skin test, this technique is more expensive and technically intricate. Tuberculin skin tests are disadvantageous because a follow-up visit is needed after 2-3 days (appendix). Few studies have addressed whether individuals with diabetes and latent tuberculosis infection are at an increased risk of progression to active tuberculosis. [50] [51] [52] Screening for latent tuberculosis infection in individuals with diabetes, in particular those with poor glycaemic control, could help to identify a highrisk population that could be off ered preventive therapy, which is not recommended but is a topic of debate within WHO. 5 Whether chemoprophylaxis is equally eff ective in individuals with or without diabetes is unknown. Only two old and potentially underpowered studies with inadequate control groups have addressed this issue. 33, 53, 54 Therefore, a randomised controlled trial of preventive tuberculosis therapy in individuals with diabetes comparative to without diabetes is a high priority. 55 
Screening for diabetes in patients with tuberculosis
Screening for diabetes in patients with tuberculosis is now widely recommended, especially where the prevalence of diabetes is high. 55 Tuberculosis control programmes in India and the Pacifi c Islands region both advocate screening in this group. 56, 57 The Pacifi c Islands region has a particularly high prevalence of diabetes with up to a third of adults aff ected, and hence diabetes screening is recommended for all adults older than 18 years with tuberculosis. Both programmes recommend repeat testing for diabetes after 2-4 weeks of tuberculosis treatment or in patients who develop symptoms of hyperglycaemia during treatment. 
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However, the best time and methods to diagnose diabetes in patients with tuberculosis are unclear. 40, 46, 55 The prevalence of diabetes rises steeply with age, but the most effi cient age cut-off for screening is also unclear and varies between populations. Measurement of blood glucose concentrations at a single timepoint might lead to a false diagnosis of diabetes in patients with tuberculosis because they could have intermittent hyperglycaemia through induction of insulin resistance, mediated by infl ammation, due to tuberculosis infection. [20] [21] [22] [23] [24] 58 Repeat testing could identify transient hyperglycaemia. Assessment of HbA 1c concentration is the only diabetes test that shows average glycaemia over time and in a single study, 59 was more sensitive than fasting blood glucose when used as a screening test for newly diagnosed diabetes in patients with tuberculosis. The point at which patients with tuberculosis are screened for diabetes is probably important. In studies identifi ed by a systematic review, 33 four described diabetes screening before tuberculosis treatment, seven after treatment initiation, four at several diff erent follow-up times, and seven studies did not specify the screening timepoint. If screening at treatment initiation is done, a second test during tuberculosis treatment, or after treatment completion, seems logical.
In low-income and middle-income countries with a high tuberculosis burden, the tests used for diabetes screening are likely to be dictated by local circumstances such as health-care set-up, opportunities for patient follow-up, and costs associated with the tests. 40, 45, 46, 55 Large studies in India and China have shown that fasting blood glucose and random blood glucose measurements can be done in tuberculosis clinics (appendix). 40, 45, 46 Various other tests are feasible for use, but their cost-eff ectiveness has not been investigated. 17, 36, [40] [41] [42] [43] [44] [45] [46] [47] Improved diabetes screening approaches in patients with tuberculosis might emerge as promising new techniques become available, including point-of-care HbA 1c assays, non-invasive advanced glycation end product readers, and sudomotor function-based screening. 60 Diff erent methods used for diabetes screening might have potential pitfalls associated with their use in patients with tuberculosis (table 2) .
Clinical presentation
Two systematic reviews 64, 65 reported no strong evidence of diff erences in radiographic presentation of tuberculosis in patients with or without diabetes. PCR=polymerase chain reaction. LED=light-emitting diode. *Screening completed in a general population. †Gold standard for any positive microbiological screen. 
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However, in 2014, a large case series 66 showed that tuberculosis patients with diabetes had more lung cavities and parenchymal lesions than tuberculosis patients without diabetes; among patients with diabetes these radiographic abnormalities were more common in those with poorer glycaemic control. Evidence with respect to the clinical presentation of tuberculosis in individuals with diabetes is inconsistent, although patients with tuberculosis and diabetes are usually older and heavier than the general tuberculosis population and more likely to be male. 14, 28, 64, 65 Less is known about whether diabetes phenotype is diff erent in patients with concurrent tuberculosis, but those patients with tuberculosis might be more likely to smoke, because smoking is a risk factor for tuberculosis.
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Treatment for concurrent tuberculosis and diabetes
Treatment of tuberculosis in patients with diabetes
The optimum treatment strategy for concurrent tuberculosis and diabetes is not known. Diabetes is associated with increased risk of tuberculosis treatment failure, death, and relapse, but whether optimum glucose control can partly or fully mitigate these negative eff ects, and whether tuberculosis treatment should be adjusted in patients with diabetes is uncertain. Treatment of drug-susceptible tuberculosis is highly standardised and usually consists of two drugs (rifampicin and isoniazid) that are taken for 6 months, combined with another two drugs (pyrazinamide and ethambutol) for the fi rst 2 months of treatment. In general, patients with tuberculosis and diabetes are not treated diff erently than patients with only tuberculosis. However, this approach might need to be reconsidered. Increases in rates of tuberculosis treatment failure in patients with diabetes are unlikely to be due to high rates of M tuberculosis drug resistance or low treatment compliance. 65 Alternative causes of treatment failure could be more extensive tuberculosis disease, 66 an altered immune response in people with diabetes (although this theory is largely speculative), or reduced concentrations of antituberculosis drugs in patients with diabetes.
In Indonesia, exposure to rifampicin (area under the curve) and maximum rifampicin plasma concentrations during the continuation phase of tuberculosis treatment were about 50% lower in tuberculosis patients with diabetes than they were in age-matched and sex-matched patients with tuberculosis without diabetes. 68 After correction for bodyweight, which was 20% higher in individuals with diabetes and tuberculosis, diabetes was still associated with reduced exposure to rifampicin and reduced plasma rifampicin concentrations were associated with more profound hyperglycaemia in patients. 68 In contrast, no diff erences were evident in full curve pharmacokinetics of rifampicin, pyrazinamide, and ethambutol during the intensive phase of tuberculosis treatment of patients with diabetes and weight-matched patients with pulmonary tuberculosis without diabetes, and no evidence for decreased bioavailability of oral rifampicin in patients with diabetes. 69 In Peru, no diff erences were recorded for 2 h and 6 h rifampicin plasma concentrations during the intensive phase of tuberculosis treatment between patients with or without diabetes. 70 Overall, these and other studies suggest that diabetes could aff ect the pharmacokinetics of tuberculosis drugs. Additionally, a heavier bodyweight might decrease rifampicin exposure, especially during the continuation phase of tuberculosis treatment. Therefore, doses of tuberculosis drugs should be adjusted according to a patient's weight, although this strategy might be diffi cult when fi xed drug combinations are used. Even if diabetes is not associated with reduced drug concentrations, an increased rifampicin dose could improve tuberculosis treatment outcomes. 71, 72 Another option to improve tuberculosis treatment outcomes in patients with diabetes might be to extend treatment duration, a possibility that is advocated in some guidelines but has yet to be formally studied. However, toxic eff ects of fi rst-line antituberculous drugs, especially peripheral neuropathy with respect to isoniazid and ocular toxic eff ects with respect to ethambutol, should be considered as these could be more common because of, or add to, complications of diabetes. 73 Ethambutol dosing frequency should be decreased when patients with diabetes have reduced kidney function.
Treatment of diabetes in patients with tuberculosis
Optimal glycaemic control might improve outcomes of tuberculosis treatment and prevent many of the complications associated with diabetes. However, tuberculosis often leads to decreases in appetite, bodyweight, and physical activity (patients might be tired and therefore less active), all of which might aff ect glucose homoeostasis. Conversely, tuberculosis treatment can have opposite but unpredictable eff ects by decreasing infl ammation, and increasing appetitie, body weight, and physical activity (fi gure 2). Although, some patients might have a paradoxical increase in infl ammation or a small apetite as a side-eff ect of the tuberculosis drugs. Infl ammation associated with active tuberculosis could cause insulin resistance, which is usually reversed once tuberculosis is treated. Additionally, good glycaemic control is dependent on the quality of the health-care system. To achieve good glycaemic control, an aggressive approach for diabetes management in patients with tuberculosis has been suggested. 74 However, this approach should be balanced against the possible harm and additional eff orts needed for implementation. Personalised pragmatic glycaemic targets might be needed that account for an array of factors, such as severity and prognosis of a given patient's tuberculosis disease, risk of adverse events such as hypoglycaemia, duration of diabetes, comorbidities, Series age, patient capabilities and treatment preferences, and available resources. 75 Frequent monitoring is needed to ensure good glycaemic control. Self-measurement of blood glucose is not feasible in many settings and for some patients. Clinic-based measurement of fasting blood glucose is not ideal for ambulatory care in busy clinics in tuberculosis-endemic settings, and random blood glucose and glycosuria measurements are less accurate than fasting blood glucose. 76 With respect to the choice of diabetes drugs, possible drug-drug interactions should be taken into account, especially for rifampicin, the most important antituberculosis drug because it helped to shorten tuberculosis treatment time from 18 to 6 months. Drug resistance to rifampicin is associated with poorer treatment outcomes, worse than for any other tuberculosis drug. Rifampicin increases the hepatic metabolism of all sulphonylurea derivatives, the most widely used class of oral diabetes drugs worldwide. This eff ect on sulphonylurea derivatives has great interindividual variation, which makes dose adjustments diffi cult and increases a patient's risk of hyperglycaemia or hypoglycaemia. Inter-individual variation in the induction of the metabolism of diabetes drugs makes dose adjustment diffi cult when rifampicin treatment is interrupted or stopped; the same is true for most other oral antidiabetes drugs (appendix). Less is known about newer antidiabetes drug classes, and no data have been published from patients with tuberculosis treated with these drugs. Rifampicin probably has no eff ect on the exposure of glucagon-like peptide-1 receptor agonists and only a slight eff ect on dipeptidyl peptidase-4 inhibitors; 77 however, poor availability and high costs of these drugs will restrict their use in tuberculosisendemic settings.
Several other factors determine the choice of antidiabetes drugs to be used in patients with tuberculosis, such as availability, cost, ease of administration, and safety. Safety concerns include hypoglycaemia with sulphonylureas and insulin, lactic acidosis (especially under hypoxic conditions) with beguanides, and gastrointestinal complaints wih biguanides, meglitinides, and alphaglucosidase inhibitors, and hypersensitivity to sulphonylureas (which might overlap with side-eff ects of antituberculous drugs). Insulin use at the start of tuberculosis treatment has been suggested; 74 some national treatment guidelines (for instance in Indonesia) strongly suggest the use of insulin for diabetes in patients with tuberculosis even though no evidence base lends support to that approach. Because insulin is not metabolised, it has no pharmacokinetic interactions with rifampicin or other antituberculous drugs, but insulin has several potential drawbacks when used in under-resourced settings including cost, availability, storage, and delivery.
Metformin is a fi rst-line drug for type 2 diabetes and does not usually lead to hypoglycaemia. Metformin is not metabolised by P450 enzymes, 78 and thus its concentrations should not be decreased by an inductive eff ect of rifampicin on these metabolic enzymes. However, exposure to metformin could be aff ected because metformin is a substrate for human organic cation transporters and other transporters. 77 Rifampicin increases the expression of organic cation transporter (OCT1) and hepatic uptake of metformin, leading to an enhanced glucose-lowering eff ect in healthy indi viduals. 79 Possible disadvantages of metformin use in patients with tuberculosis include the risk of gastrointestinal sideeff ects and, very rarely, lactic acidosis. 80, 81 Drug-drug interactions are even more probable when patients with tuberculosis also have HIV, because many anti-HIV drugs are substrates of metabolic or transporter enzymes, or can change the activity of these enzymes. Similarly, toxicity profi les and side-eff ects of HIV, tuberculosis, and diabetes drugs might overlap. To our knowledge, no studies on the combined treatment of these three diseases have been published.
What is needed for patients with concurrent tuberculosis and diabetes?
Patients with tuberculosis and diabetes might need alternative interventions besides changes to their drug regimens. Counselling and education are advised for patients with tuberculosis and newly diagnosed diabetes. In an Indonesian study, 60% of cases of diabetes in patients with tuberculosis were newly diagnosed. 82 To refer a patient with active tuberculosis to a separate diabetes clinic is not an option that appeals, both from a patient's and an infectious control point of view. However, patients that need insulin, in particular, need to learn about glucose measurements and the symptoms and necessary action in case of hypoglycaemia. Intense engagement of patients with tuberculosis with the health system, especially early on in their treatment, provides an opportunity for repeated counselling including about lifestyle interventions (eg, nutrition, weight loss, smoking 
Active tuberculosis
Inflammation leading to: weight loss; loss of appetite; insulin resistance Behaviour Variable food intake; physical activity; treatment compliance Health systems Access and affordability of health services; collaboration between tuberculosis and diabetes physicians; laboratory facilities; continuous medicaton supply
Drug therapy
Side-effects (eg, vomiting); drug-drug interactions; weight gain during treatment Series cessation, and physical activity). 83 In the Pacifi c Islands region, extensive educational materials have been developed for patients with tuberculosis and diabetes. 84 Patients with concurrent tuberculosis and diabetes might have specifi c needs during treatment follow-up.
Monitoring of liver and kidney functions might need to be more intense than in patients with only tuberculosis. Although not part of routine practice in tuberculosis clinics, international guidelines recommend regular measurements of blood pressure and lipid profi les for individuals with diabetes, with low thresholds to start antihypertensive drugs or statin therapy. Aspirin is indicated for secondary prevention in patients with cardiovascular events and could be used as a general primary prevention strategy. 83 To consider all of the aforementioned issues in some patients-such as those who are very unwell with tuberculosis or who have co-infection with HIV, drugtoxicity, substance misuse issues, psychiatric comorbidity, or poor compliance to tuberculosis treatment-is unrealistic. However, the long-term prognosis of patients with uncomplicated tuberculosis, or of those who quickly recover, might depend heavily on the management of their diabetes. A patient's diabetes phenotype at the time of completion of their tuberculosis treatment-in terms of HbA 1c concentrations, diabetes treatment, BMI, blood pressure, lipid profi le, proteinuria, smoking, and alcohol consumption-will determine their long-term need for lifestyle interventions and antidiabetic, antihypertensive, lipid-lowering, anti platelet, and other drugs (panel 2). After completion of tuberculosis treatment, individuals with diabetes need continued diabetes management and a heightened alertness for tuberculosis symptoms because relapse is common in these patients. 4 
Implications for health service delivery and health economics
The integration of services for tuberculosis and diabetes should lead to better tuberculosis control and early diagnosis and treatment of diabetes, which will improve the alignment of treatment, monitoring, and counselling of patients with both diseases. Improved outcomes that result from such integration could lead to effi ciency gains in terms of patient care. However, integration might overwhelm already overburdened and understaff ed programmes. 85 Unfortunately, diabetes management in low-income and middle-income countries rarely meets evidence-based standards. 86 Very often the public's awareness of both diseases is low, diagnostic services and trained specialists are scarce, and diabetes treatments are restricted because of the low supply and high cost of drugs. 86, 87 In many low-income and middle-income countries, diabetes monitoring and treatment are only partly covered by health insurance or government support. In Peru, for example, diabetes care for patients with tuberculosis is only covered for the duration of their tuberculosis treatment-after completion, the costs are the patient's responsibility.
Although similar problems once existed for tuberculosis and HIV in under-resourced settings, substantial progress occurred during the past 10-20 years. Integration of services has led to increased uptake of services by patients, 
Infection control
Diabetes clinic might not be equipped or be poorly equipped for tuberculosis infection control
Tuberculosis treatment
Increased duration of treatment and weight-adjusted doses of antituberculous drugs might be necessary
Diabetes treatment
No evidence-based recommendations are available for diabetes therapy choice; diff erent approaches might be needed for newly diagnosed and previously diagnosed diabetes
Drug-drug interactions
Rifampicin increases metabolism of antidiabetes drugs, except insulin and metformin; HIV treatment is likely to incur additional interactions
Treatment adherence
Disease symptoms, high pill load, and side-eff ects could compromise treatment adherence in patients with both diseases
Monitoring
Intense monitoring and follow-up might be needed because of increased likelihood of toxic eff ects of drugs, failure, and relapse rates; active tuberculosis screening might be worthwhile in patients with diabetes who previously had tuberculosis because of high recurrence rates
Glycaemic control
Potential logistical issues to measurement of glycaemic control in the tuberculosis clinic; decisions for adjustment of diabetes drug is dependent on glucose concentrations and various other factors
Coordination of care
Treatment delivery by separate clinics or diff erent specialists could lead to confl icts in advice on treatment and safety issues Counselling and education Needs to address both tuberculosis and diabetes; intense counselling is needed for patients starting insulin therapy
Lifestyle and smoking
Patients should be actively engaged in adoption of healthy lifestyle changes to address issues such as smoking and obesity
Continuation of care
Patients with tuberculosis and newly diagnosed diabetes need to be referred for chronic diabetes care once tuberculosis treatment is completed improved treatment outcomes, and decreased mortality rates. 88, 89 The experience and methods used to address the burden of tuberculosis and HIV-such as evidence-based clinical algorithms, measures to control tuberculosis infections, point-of-care diagnostics, so-called task-shifting, and innovative health service delivery (panel 3)-could be adapted for integrated tuberculosis and diabetes care. For instance, through use of standardised cohort recording and reporting methods in the tuberculosis and HIV DOTs (directly observed therapy, short course) 99 and of real-time electronic medical record systems at the point of care (so called E-health), the rates of diabetes, measures of diabetes service performance (eg, proportion of patients with blood pressure measurements), and treatment results were reported for thousands of Palestinian refugees. 100, 101 Tuberculosis treatment programmes can also learn from patient's self-monitoring experiences, with or without peer support, for use in diabetes care. 102 Assessments of the cost-eff ectiveness of bidirectional screening for tuberculosis and diabetes, and the integration of treatments for both diseases have not been done. An early diagnosis of diabetes and intense monitoring of blood glucose concentrations is expected to result in earlier and improved glycaemic control, leading to improved health outcomes. However, the overall costs of treatment for diabetes and associated comorbidities could increase. Screening tests for diabetes vary substantially in cost and resources needed (table 2); evidence from low-income and middle-income countries suggests that the most cost-eff ective approach might include a risk score with confi rmatory blood testing 103 (recommended by the International Diabetes Federation and the UK Health Technology Assessment Programme 63, 104 ). The presence of tuberculosis could be a contributor to such risk scores, although this eff ect has not been investigated. Tighter glycaemic control is resource intensive and might place a burden on patients in terms of out-of-pocket costs for care, which could aff ect adherence to treatment. A less intense schedule of glucose monitoring, preferably following the established decision points in tuberculosis treatment after 2 and 6 months, would off er substantial advantages in terms of costs and burden on the patient. An ongoing pragmatic randomised clinical trial (NCT02106039) 105 in patients with tuberculosis and diabetes in Peru, Romania, South Africa, and Indonesia will defi ne the requirements for good glycaemic control by comparison with standard versus intensifi ed glucose monitoring.
Evidence is scarce with respect to the cost-eff ectiveness of screening for tuberculosis in patients with diabetes. The yield will probably be very low, except in regions with a very high incidence of tuberculosis. 5, 33, 40, 45 However, about half of people with diabetes are undiagnosed globally, and many people with diabetes in low-income and middle-income countries are not on appropriate treatments. Moreover, about 30% of patients with tuberculosis are undiagnosed. Thus bidirectional screening would decrease the proportion of undiagnosed individuals with tuberculosis or diabetes, and integrated screening and care will enable patients with both diseases to receive appropriate treatments. 
Clinical algorithms
Evidence-based algorithms for bidirectional screening and combined treatment of tuberculosis and HIV have been developed 40, 45, 46 Tuberculosis chemoprophylaxis Tuberculosis chemoprophylaxis (isoniazid preventive therapy) is indicated for all patients with HIV once active tuberculosis is excluded; implementation might be easier in patients with diabetes as active tuberculosis can more reliably be excluded in patients with diabetes than in those with HIV; however, the effi cacy of such preventive treatment is unknown [50] [51] [52] Health promotion Training materials and other techniques used for HIV alone and combined HIV and tuberculosis can be adapted to create methods for lifestyle interventions for patients with concurrent tuberculosis and diabetes
Tuberculosis infection control
Evidence-based policies are available for implementation of sound tuberculosis infection control in health-care facilities, including use of available spaces, separation of infectious patients, tuberculosis surveillance and preventive therapy for health workers, and environmental controls such as ventilation systems 90 
Decentralisation of health services
Mobile units have a high yield for combined screening of HIV, tuberculosis, diabetes, and hypertension in South Africa; 91 linking to chronic care is challenging; successful community engagement (eg, in work sites and households) used for tuberculosis and HIV could be adapted for tuberculosis and diabetes Human resources, task shifting Task shifting from physician to non-physician and to lay health worker to combat growing burden of disease is safe and cost-eff ective [92] [93] [94] Drug delivery Combination of treatments for several diseases leads to strengthening of health systems (eg, supply chain, laboratory services) and increases accessibility and availability of care; tuberculosis and HIV treatment is free, diabetes treatment often is not Point-of-care diagnosis Point-of-care diagnosis of HIV and tuberculosis has led to improved access to care and early treatment; point-of-care HbA 1c testing might have similar eff ects to increase diagnosis and care of diabetes in under-resourced settings 95 Standardised recording and reporting Cohort records and reports from the DOTs (directly observed therapy, short course) framework were adapted and used to monitor individuals with diabetes in Malawi; 96 tuberculosis treatment cards and registers might need modifi cations to capture information on diabetes screening and diagnosis, just as with HIV
Adherence and retention to care
Various strategies have helped sustain long-term adherence and retention to care, including empowered patients, 97 who are actively invovled in their own medical care, and mobile phone technology 98 
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Conclusions
The prevalence of diabetes in patients with tuberculosis will continue to increase as a result of the rising global burden of type 2 diabetes. Although screening patients with tuberculosis for diabetes is recommended, many questions are unanswered with respect to the best way
Search strategy and selection criteria
We searched Medline, Embase, and Web of Science between each database's inception date and May 31, 2014, for articles in English using the search terms (alone or in combination) "diabetes", "tuberculosis", "risk factors", "outcomes", "epidemiology", "survival analysis", "low and middle income countries (LMIC)", "low resource"; "screening", "blood glucose", "fasting blood glucose", "HbA1c", "tuberculin test", "IGRA", "Xpert TB", "computer-aided", "point-of care"; "diabetes guidelines", "patient management", "treatment", "treatment adherence", "radiographic manifestations", "pharmacokinetics", "rifampicin" and other fi rst line tuberculosis drugs in combination with each of the diabetes drugs; "cost", "(health)-economic", "cost-eff ectiveness", "cost analysis"; "smoking", "non-communicable disease", "communicable disease", "comorbidity", "HIV", "health system", "task shifting", "infection control", "(chemo) prophylaxis". We manually searched the references of individual articles for additional publications that were not previously identifi ed. A predefi ned maximum of 110 articles was selected based on relevance to a pre-specifi ed review outline, scientifi c strength, and date of publication. We did not have exclusion criteria; however, if many references were available the papers of a higher scientifi c quality and of a more recent date were chosen.
to implement screening in diff erent settings. Screening patients with diabetes for active tuberculosis could be considered but the best clinical algorithm needs to be identifi ed and cost-eff ectiveness remains to be established. Good glycaemic control might improve health outcomes when tuberculosis and diabetes are simultaneously treated. Tuberculosis treatment monitoring might need to be more intensive if patients with tuberculosis also have diabetes. Additionally, other interventions should be considered, especially for patients with newly diagnosed diabetes and for people who need insulin. More evidence is needed to support screening and subsequent treatment for latent tuberculosis infections in patients with diabetes. Integration of health services could result in better tuberculosis prevention, an early diagnosis and start of treatment for diabetes, and improved care for concomitant disease. However, the practical and economic implications need further assessment before they are implemented and many key research questions need to be answered (panel 4). Clearly, there is a call to clinicians and researchers to generate the necessary evidence for improvements to patient services and policies with respect to combined tuberculosis and diabetes.
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